|
|
|
|
|
Sufentanil
drug data and news
Sufentanil drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Sufentanil | ||
| Brand Names/Synonyms | Chronogesic; Dea No. 9740; HSDB 6760; R-30730; Sufenta; Sufentanil; Sufentanil Base; Sufentanil Citrate; Sufentanil [Usan:Ban:Inn]; Sufentanilum [Inn-Latin]; Sufentanyl; Sulfentanil Citrate | ||
| Indication | Used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Sufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Sufentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Sufentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. | ||
| Mechanism Of Action | Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. | ||
| Sufentanil News (When available) |
Endo Pharmaceuticals Reports First Quarter 2006 Financial Results Apr 20, 2006 | ||
| Dosage Forms | LIQUID; SOLUTION | ||
| Drug_Category | Anesthetics, Intravenous; Narcotics; Adjuvants, Anesthesia; Analgesics, Opioid; Opiate Agonists; ATC:N01AH03 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Sufentanil: May interact with the following: any other medicine, prescription or nonprescription (over-the-counter [OTC]), or street drugs, such as amphetamines, barbiturates, cocaine, marijuana, phencyclidine, and heroin or other narcotics (serious side effects may occur if anyone gives you an anesthetic without knowing that you have taken another medicine), benzodiazepines, central nervous system (CNS) depressants (the CNS depressant and other effects of either these medicines or the narcotic analgesics may be increased), buprenorphine or similar medicines (the narcotic analgesics may not work if you are taking buprenorphine or other similar medicines), cimetidine, erythromycin (increased chance of side effects with some narcotic analgesics), and naltrexone (the narcotic analgesics will not work if you are taking naltrexone). | ||
| Toxicity | Intravenous, mouse LD50: 18.7 mg/kg | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)-4-piperidyl]-N-phenyl-propanamide | ||
| Chemical Formula | C22H30N2O2S | ||
| Molecular Weight | 386.552 g/mol | ||
| Smiles String | CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC | ||
| Melting Point | 97 °C | ||
| Water Solubility | 76 mg/L | ||
| State | Solid (white granules or powder) | ||
| LogP/Hphobicity | 3.382 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 265 minutes | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Sufentanil.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00671 | ||
| CAS Registry Number | 56030-54-7 | ||
| KEGG Compound ID | C08022 | ||
| PubChem ID | SID:10222 | ||
| PharmGKB ID | PA451527 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2244147 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |